Dr. Dellaripa w/great talk on digital ischemia. Presents case of 25 yo F w/SLE, Class IV LN, APS, on apixaban, MMF, HCQ admitted w/AKI, ⬆️Upro & U-blood -> new HFrEF (EF 22%), tachy, & digital ischemia w/skin bx = thrombotic vasculopathy. #ACR21 Scientific Session 9T114 @RheumNow

Had a blast with the @RheumNow team covering #ACR21! Eager to pour over more material over the coming weeks. What did folks do before the abstracts and videos were available online??

Third Time's the Charm - COVID Vaccination While on Rituximab: Dr. Yuz Y... https://t.co/uxA00n1hxy via @YouTube Do watch my short commentary on the enhanced immuno-protection of 3rd primary #COVID dose in patients who are treated with rituximab #ACR21 @RheumNow

• Third Time's the Charm - COVID Vaccination While on Rituximab: Dr. Yuz Yuso…

Risk of retinopathy vs #lupus flares. Do watch my interview with Dr Jorge on her works on issues surrounding hydroxyxhloroquine dose #ACR21 @RheumNow https://t.co/hKsAi4dD2n

• Hydroxychloroquine Dose and Risk of Lupus Flare: Drs. Yuzaiful Yusof and April …

Watch the @RheumNow #rheumatoidarthritis panel discuss some of our highlights from #ACR21! https://t.co/Q5Yps3s165

• RA Panel: Safety, Multimorbidities, Vaccination and the Weather | RheumNow

Do watch the Autoinflammatory Faculty @RheumNow discussed a selection of data presented at #ACR21 @uptoTate @bella_mehta @DrPetryna Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in i... https://t.co/4biuKzWLBc via @YouTube

• Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infe…

Impromptu #TeamSparks video meeting with 2nd year fellows @KronzerMD and Dr Gregory McDermott detailing our research findings from the @MassGenBrigham Biobank (funded by @NIH_NIAMS and VERITY) @OrACORe_BWH @MayoClinic @RheumNow #ACR21 https://t.co/CQ9XDamb0E

So I think the talk of #ACR21 has been ORAL Surveillance, the phase 3b/4 @US_FDA post-marketing requirement study of tofacitinib vs TNFi in CV risk pts. I've tried to capture this live through a few threads/tweets, as it happened. Catch up via this thread of threads @RheumNow

Dr. Aurelie Nahm ( @AurelieRheumo) shares #ACR21 presentation findings on TNF inhibitors and radiographic progression in axSpA https://t.co/FPs43SGH5R https://t.co/MeM1Js5p4n

• https://bit.ly/3o4cvM2

Sinusitis and Pharyngitis with Incident RA: Dr. Richard Conway discusses abstract #0564 presented at the #ACR21 annual meeting. https://t.co/rWS8VT5obl https://t.co/cHLTf9HPWe

• https://bit.ly/3mU9Chl

RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.

Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX

📢No difference in ESRD or mortality with RTX-based vs CYC-based induction regimen in ANCA #Vasculitis #ACR21 https://t.co/Bdz5t2uyHi

#ACR21 #ACR2021 Extra pulmonary sarcoidosis ➡️ Cutaneous Sarcoidosis 👌🏻 talk not posting a tweetorial for the talk as I would suggest go see the talk once masterclass in Cutaneous sarcoidosis https://t.co/vkWXkq7DXF